Ozempic (Semaglutide) Nausea: When to Call the Doctor

How common is nausea on Ozempic?

In the pooled trials, 262 people received placebo, 260 received Ozempic 0.5 mg and 261 received Ozempic 1 mg. Mean exposure to Ozempic was 32.9 weeks [1]. Nausea was reported by 6.1% on placebo, 15.8% on 0.5 mg and 20.3% on 1 mg [1].

The other GI reactions were also more common on Ozempic than on placebo, though not every one rose from 0.5 mg to 1 mg:

• Vomiting: 2.3% on placebo, 5% on 0.5 mg, 9.2% on 1 mg [1]
• Diarrhea: 1.9%, 8.5%, 8.8% [1]
• Abdominal pain: 4.6%, 7.3%, 5.7% [1]
• Constipation: 1.5%, 5%, 3.1% [1]

Any gastrointestinal reaction was reported by 15.3% on placebo, 32.7% on 0.5 mg and 36.4% on 1 mg, and treatment was stopped for GI reasons in 0.4%, 3.1% and 3.8% respectively [1]. Severe GI reactions were far less common: 0.4% at 0.5 mg, 0.8% at 1 mg and 0% on placebo [1].

The step from 1 mg to 2 mg has its own comparison. In a 40-week trial of 959 people, GI reactions occurred in 34% on 2 mg and 30.8% on 1 mg, with no new safety signals [1].

When does nausea need medical attention?

The label's warnings are the most concrete guide to when symptoms stop being routine [1].

Persistent or severe belly pain

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists including Ozempic. The label says to watch for persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, the label says to discontinue Ozempic and initiate appropriate management [1].

Vomiting or diarrhea that causes dehydration

The label reports postmarketing cases of acute kidney injury, some requiring hemodialysis. Most occurred in people who had GI reactions such as nausea, vomiting or diarrhea that led to dehydration. It says to monitor renal function in people with reactions that could lead to volume depletion, especially during dose initiation and escalation [1].

Severe GI reactions, ileus and obstruction

Ozempic is not recommended in people with severe gastroparesis. Postmarketing reports listed in the label include ileus, intestinal obstruction and severe constipation with fecal impaction [1]. The label does not state that semaglutide causes gastroparesis [1].

Signs of a hypersensitivity reaction

Anaphylaxis and angioedema are listed among the serious hypersensitivity reactions reported with Ozempic. The label says to discontinue Ozempic if a hypersensitivity reaction is suspected and to promptly seek medical advice, and that the reaction should be treated per standard of care and monitored until signs and symptoms resolve [1].

Does a slower dose increase reduce nausea?

The label's schedule is 0.25 mg once weekly for 4 weeks, then 0.5 mg; 1 mg after at least 4 weeks on 0.5 mg; and 2 mg after at least 4 weeks on 1 mg, with 2 mg weekly as the maximum [1]. The label calls 0.25 mg a starting dose, not a maintenance dose [1].

Most reports of nausea, vomiting and diarrhea occurred during dose escalation [1]. The label does not establish whether waiting longer between increases reduces nausea. The injection itself is flexible: once weekly, on the same day each week, at any time of day, with or without meals [1].

If you use compounded semaglutide

Ozempic's trial numbers and dose steps describe the FDA-approved pen. Compounded semaglutide is not FDA approved and is not reviewed for safety, effectiveness or quality before marketing. FDA has received adverse event reports involving compounded semaglutide and warns about dosing errors [2].